Logo image of MITRA.BR

Mithra Pharmaceuticals SA (MITRA.BR) Stock Fundamental Analysis

EBR:MITRA - Euronext Brussels - BE0974283153 - Common Stock - Currency: EUR

0.216  0 (-1.82%)

Fundamental Rating

2

Taking everything into account, MITRA scores 2 out of 10 in our fundamental rating. MITRA was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MITRA have multiple concerns. While showing a medium growth rate, MITRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MITRA has reported negative net income.
In the past year MITRA has reported a negative cash flow from operations.
In the past 5 years MITRA always reported negative net income.
MITRA had a negative operating cash flow in each of the past 5 years.
MITRA.BR Yearly Net Income VS EBIT VS OCF VS FCFMITRA.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.04%, MITRA is doing worse than 71.74% of the companies in the same industry.
Industry RankSector Rank
ROA -21.04%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MITRA.BR Yearly ROA, ROE, ROICMITRA.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

1.3 Margins

With a Gross Margin value of 66.54%, MITRA perfoms like the industry average, outperforming 45.65% of the companies in the same industry.
In the last couple of years the Gross Margin of MITRA has declined.
The Profit Margin and Operating Margin are not available for MITRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.77%
GM growth 5Y-14.16%
MITRA.BR Yearly Profit, Operating, Gross MarginsMITRA.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

MITRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
MITRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MITRA.BR Yearly Shares OutstandingMITRA.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
MITRA.BR Yearly Total Debt VS Total AssetsMITRA.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

MITRA has an Altman-Z score of -1.88. This is a bad value and indicates that MITRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.88, MITRA is not doing good in the industry: 71.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.88
ROIC/WACCN/A
WACC3.99%
MITRA.BR Yearly LT Debt VS Equity VS FCFMITRA.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

MITRA has a Current Ratio of 1.04. This is a normal value and indicates that MITRA is financially healthy and should not expect problems in meeting its short term obligations.
MITRA's Current ratio of 1.04 is on the low side compared to the rest of the industry. MITRA is outperformed by 80.43% of its industry peers.
MITRA has a Quick Ratio of 1.04. This is a bad value and indicates that MITRA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MITRA (0.49) is worse than 89.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.49
MITRA.BR Yearly Current Assets VS Current LiabilitesMITRA.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

MITRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.70%, which is quite impressive.
Looking at the last year, MITRA shows a very strong growth in Revenue. The Revenue has grown by 186.41%.
MITRA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.05% yearly.
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
Revenue 1Y (TTM)186.41%
Revenue growth 3Y64.44%
Revenue growth 5Y-7.05%
Sales Q2Q%-38.06%

3.2 Future

The Earnings Per Share is expected to grow by 40.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, MITRA will show a very strong growth in Revenue. The Revenue will grow by 80.47% on average per year.
EPS Next Y32.9%
EPS Next 2Y49.56%
EPS Next 3Y40.23%
EPS Next 5YN/A
Revenue Next Year175.31%
Revenue Next 2Y104.65%
Revenue Next 3Y80.47%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MITRA.BR Yearly Revenue VS EstimatesMITRA.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
MITRA.BR Yearly EPS VS EstimatesMITRA.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MITRA. In the last year negative earnings were reported.
Also next year MITRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MITRA.BR Price Earnings VS Forward Price EarningsMITRA.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MITRA.BR Per share dataMITRA.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as MITRA's earnings are expected to grow with 40.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.56%
EPS Next 3Y40.23%

More info and screens

0

5. Dividend

5.1 Amount

MITRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Mithra Pharmaceuticals SA

EBR:MITRA (4/26/2024, 7:00:00 PM)

0.216

0 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-08 2024-03-08/amc
Earnings (Next)09-26 2024-09-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.93M
Analysts35.56
Price Target3.8 (1659.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.13%
PT rev (3m)-8.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.59%
EPS NY rev (3m)-122.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.91
BVpS-0.13
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.77%
GM growth 5Y-14.16%
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 154.6%
Cap/Sales 30.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 0.49
Altman-Z -1.88
F-Score4
WACC3.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
EPS Next Y32.9%
EPS Next 2Y49.56%
EPS Next 3Y40.23%
EPS Next 5YN/A
Revenue 1Y (TTM)186.41%
Revenue growth 3Y64.44%
Revenue growth 5Y-7.05%
Sales Q2Q%-38.06%
Revenue Next Year175.31%
Revenue Next 2Y104.65%
Revenue Next 3Y80.47%
Revenue Next 5YN/A
EBIT growth 1Y50.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.67%
EBIT Next 3Y44.47%
EBIT Next 5YN/A
FCF growth 1Y71.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.66%
OCF growth 3YN/A
OCF growth 5YN/A